BERLIN -- Almost half of patients with advanced ALK -positive non-small cell lung cancer (NSCLC) have lived 7 years or longer ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

A systematic review reveals poor assessment and reporting of health-related quality of life (HRQoL) in early-stage NSCLC ...

Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.

"ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate" was originally created and published by Clinical ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ...

Across studies assessing the efficacy of immune checkpoint inhibitors (ICIs) or tyrosine kinase inhibitors (TKIs) in early-stage non–small cell lung cancer (NSCLC), researchers found that ...

Dr. Sandip Patel discusses findings from a real-world study of biomarker testing in early-stage resected non-small cell lung cancer in the U.S. Although biomarker testing in early-stage non-small cell ...

In August, Zongertinib received FDA approval for previously treated HER2-mutant NSCLC. It now shows efficacy in first-line ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo 1 IMvigor011 is the first global phase III study to read out pioneering a ctDNA- ...

Tagrisso combined with chemotherapy improved overall survival in EGFR-mutated NSCLC patients, including those with poor ...